"rationale","instanceType","id","uuid:ID","versionIdentifier"
"The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","StudyVersion","StudyVersion_1","98530c33-e3d6-452f-a6dd-59c2ed649505","2"
